Oral immunotherapy and Viaskin Peanut for peanut allergy: effectiveness and value : final evidence report
- Collection:
- Health Policy and Services Research
- Author(s):
- Tice, Jeffrey A., author Herron-Smith, Serina, author Tsiao, Emily, author Chapman, Rick M., author Zaim, Remziye, author Segel, Celia, author Rind, David, author Pearson, Steven D., author Guzauskas, Greg, author Hansen, Ryan N., author
- Contributor(s):
- California Technology Assessment Forum, issuing body. Institute for Clinical and Economic Review, issuing body.
- Publication:
- [Boston, Massachusetts] : Institute for Clinical and Economic Review, July 10, 2019
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Immunotherapy Peanut Hypersensitivity United States
- Genre(s):
- Technical Report
- Abstract:
- Peanut is a common childhood allergen in the United States (US). According to recent estimates approximately 1.4-4.5% of children in the US suffer from peanut allergy. In addition, peanut allergy is the leading cause of death from anaphylaxis due to food, particularly in teenagers, though the rate is low. The national food allergy death registry reports fewer than four deaths per year over the past 10 years in the US. The economic cost of food allergies in the US is estimated at $24.8 billion per year, of which only $4.3 billion was direct medical costs. Non-medical costs accounted for $20.5 billion and included out-of-pocket medical costs, the costs of special foods, and lost caregiver productivity. The primary approach to managing food allergies is to avoid the trigger. Epinephrine is used first line for anaphylaxis, often administered by the patient or family using an autoinjector. Research has focused on desensitizing patients by exposing them to increasing amounts of the food, but no therapies are FDA approved. Desensitization means that patients are less likely to react to an accidental exposure to peanut protein with ongoing treatment, but does not imply tolerance – the ability to eat any amount of food containing peanuts without risk of a serious reaction. This evidence review examines the effectiveness and value of two technologies to desensitize patients with peanut allergy that are expected to be approved by the FDA—AR101 and Viaskin® Peanut—as well as non-commercialized oral immunotherapy (OIT) for peanut allergy.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
- Extent:
- 1 online resource (1 PDF file (various pagings))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 9918401083906676 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/9918401083906676